Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:CMRX NASDAQ:KDNY NASDAQ:VBIV NASDAQ:VERU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$8.00-1.1%$7.97$6.10▼$28.67$560.26M1.41397,467 shs214,585 shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.83 million shsN/AKDNYChinook Therapeutics$40.39$39.86$18.34▼$40.51$2.90B0.341.19 million shsN/AVBIVVBI Vaccines$0.23$0.06▼$1.35$1.87M2.183.66 million shs29.90 million shsVERUVeru$0.60+3.0%$0.57$0.45▼$1.42$85.49M-0.751.93 million shs1.56 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-1.11%+7.74%-8.68%+19.40%-61.92%CMRXChimerix0.00%0.00%0.00%+0.23%+918.36%KDNYChinook Therapeutics0.00%0.00%0.00%0.00%0.00%VBIVVBI Vaccines0.00%0.00%0.00%0.00%-91.32%VERUVeru+2.97%+0.08%-10.71%+10.65%-31.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCYCBicycle Therapeutics3.7292 of 5 stars4.42.00.00.02.34.20.6CMRXChimerix0.5467 of 5 stars1.00.00.04.10.01.70.6KDNYChinook TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVBIVVBI VaccinesN/AN/AN/AN/AN/AN/AN/AN/AVERUVeru2.8951 of 5 stars3.54.00.00.03.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.70Moderate Buy$25.00212.50% UpsideCMRXChimerix 2.00Hold$8.53-0.08% DownsideKDNYChinook Therapeutics 0.00N/AN/AN/AVBIVVBI Vaccines 0.00N/AN/AN/AVERUVeru 3.00Buy$4.00566.11% UpsideCurrent Analyst Ratings BreakdownLatest VBIV, BCYC, VERU, CMRX, and KDNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025BCYCBicycle TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.005/2/2025BCYCBicycle TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.005/2/2025BCYCBicycle TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.005/2/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.005/2/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/1/2025BCYCBicycle TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$35.28M15.70N/AN/A$11.48 per share0.70CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94KDNYChinook Therapeutics$6.13M473.15N/AN/A$6.91 per share5.85VBIVVBI Vaccines$9.41M0.00N/AN/A$0.32 per share0.00VERUVeru$16.89M5.21N/AN/A$0.22 per share2.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)CMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)KDNYChinook Therapeutics-$187.87M-$3.52N/AN/AN/A-4,199.93%-58.28%-44.72%N/AVBIVVBI Vaccines-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/AVERUVeru-$37.80M-$0.24N/AN/AN/AN/A-128.51%-76.51%8/6/2025 (Estimated)Latest VBIV, BCYC, VERU, CMRX, and KDNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BCYCBicycle Therapeutics-$0.95N/AN/AN/A$9.43 millionN/A5/8/2025Q2 2025VERUVeru-$0.06-$0.05+$0.01-$0.05$0.73 millionN/A5/1/2025Q1 2025BCYCBicycle Therapeutics-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AKDNYChinook TherapeuticsN/AN/AN/AN/AN/AVBIVVBI VaccinesN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A14.8614.86CMRXChimerixN/A6.336.33KDNYChinook TherapeuticsN/A5.825.82VBIVVBI VaccinesN/A0.340.21VERUVeruN/A3.803.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%CMRXChimerix45.42%KDNYChinook Therapeutics95.15%VBIVVBI Vaccines12.26%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics22.90%CMRXChimerix13.10%KDNYChinook Therapeutics16.79%VBIVVBI Vaccines10.35%VERUVeru15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.25 million53.40 millionOptionableCMRXChimerix9093.80 million78.15 millionOptionableKDNYChinook Therapeutics21471.81 million59.75 millionOptionableVBIVVBI Vaccines2228.68 million25.71 millionOptionableVERUVeru230146.58 million124.30 millionOptionableVBIV, BCYC, VERU, CMRX, and KDNY HeadlinesRecent News About These CompaniesVeru And Two Other Penny Stocks To ConsiderJune 26, 2025 | finance.yahoo.comVeru Inc (FMW.DU)June 26, 2025 | nz.finance.yahoo.comVeru reports positive results for enobosarm in weight management studyJune 26, 2025 | uk.investing.comWhy Veru Inc. Is Rising In Pre-market? - NasdaqJune 26, 2025 | nasdaq.comVeru (NASDAQ:VERU) Stock Price Crosses Below 200-Day Moving Average - Here's What HappenedJune 25, 2025 | marketbeat.comOne Veru Insider Raised Stake By 150% In Previous YearJune 22, 2025 | finance.yahoo.comScholar Rock drug preserves muscle in obesity trialJune 18, 2025 | yahoo.comTraders Buy High Volume of Put Options on Veru (NASDAQ:VERU)June 17, 2025 | marketbeat.comVeru (NASDAQ:VERU) Stock Crosses Below 200-Day Moving Average - Here's WhyJune 17, 2025 | marketbeat.comVeru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025June 11, 2025 | quiverquant.comQVeru to Participate in the Virtual BTIG Obesity Health ForumJune 11, 2025 | globenewswire.comBeyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leaveMay 30, 2025 | seekingalpha.comVeru’s obesity drug roughly as safe as Wegovy; Keros’ board fightMay 28, 2025 | endpts.comEMuscle-sparing obesity drug safe for Phase 3 trial, Veru saysMay 28, 2025 | yahoo.comVeru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with SemaglutideMay 28, 2025 | quiverquant.comQVeru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide AloneMay 28, 2025 | globenewswire.comVeru: Saving Muscle Mass Amidst The GLP-1 Drug BoomMay 26, 2025 | seekingalpha.comYoungsters at Dunstable school hear about the dangers of knife crimeMay 22, 2025 | msn.comVeru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program ProgressMay 8, 2025 | finanznachrichten.deVeru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trialMay 8, 2025 | msn.comVeru Inc. (VERU) Q2 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayVBIV, BCYC, VERU, CMRX, and KDNY Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$8.00 -0.09 (-1.11%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$7.50 -0.51 (-6.31%) As of 07/11/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Chinook Therapeutics NASDAQ:KDNYChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.VBI Vaccines NASDAQ:VBIVVBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.Veru NASDAQ:VERU$0.60 +0.02 (+2.97%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.59 -0.01 (-1.75%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
